The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.

Abstract:

:Bioavailability and therapeutic outcome of treatment with HIV-protease inhibitors depends on intestinal and hepatic transporter-enzyme interplay. Liver transport of HIV protease inhibitors (saquinavir, darunavir) was assessed in the presence of aged garlic extract, because the HIV-infected often consume garlic supplements together with prescribed therapy. The in vitro uptake of both drugs into HepG2 cells and precision cut rat liver slices significantly increased in the presence of Pgp and MRP-2 inhibitor ritonavir. The incubation medium containing aged garlic extract caused significant inhibition of saquinavir efflux from HepG2 cells and precision cut liver slices, while the activity of darunavir efflux transporters in both liver models significantly increased. Due to opposite in vitro interactions observed between aged garlic extract and HIV protease inhibitors, darunavir and saquinavir most probably bind to different binding sites on one or both efflux transporters. Based on this study, coadministration of investigated compounds with garlic supplements could result in significant in vivo modification of hepatic transport-enzyme interplay, possibly leading to further bioavailability change.

authors

Berginc K,Trontelj J,Kristl A

doi

10.2133/dmpk.25.307

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

307-13

issue

3

eissn

1347-4367

issn

1880-0920

pii

JST.JSTAGE/dmpk/25.307

journal_volume

25

pub_type

杂志文章
  • A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

    abstract::Tralokinumab is a human monoclonal antibody in clinical development for asthma and atopic dermatitis that specifically neutralizes interleukin-13. This phase I, single-blind, randomized, placebo-controlled, single ascending-dose study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of subc...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.dmpk.2017.12.001

    authors: Baverel P,She D,Piper E,Ueda S,Yoshioka T,Faggioni R,Gevorkyan H

    更新日期:2018-06-01 00:00:00

  • Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.

    abstract::The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasma samples were collected from 90 healthy volunteers and 457 patients with overactive bladder. We determined the plasma concen...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.23.456

    authors: Ohno T,Nakade S,Nakayama K,Kitagawa J,Miyabe H,Konomi T,Miyata Y

    更新日期:2008-01-01 00:00:00

  • Blood-brain permeability of [3H]-(3-methyl-His2)thyrotropin-releasing hormone (MeTRH) in mice: effects of TRH and its analogues.

    abstract::The present study was undertaken to characterize the transport of (3-methyl-His(2)) thyrotropin-releasing hormone ([(3)H]MeTRH) across the blood-brain barrier in mice and the effects of thyrotropin-releasing hormone (TRH) and its analogues (taltirelin and montirelin) on the transport and brain distribution. Integratio...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.18.310

    authors: Urayama A,Yamada S,Ohmori Y,Deguchi Y,Uchida S,Kimura R

    更新日期:2003-01-01 00:00:00

  • Population pharmacokinetic and exposure-response analyses of guanfacine in Japanese pediatric ADHD patients.

    abstract::Guanfacine hydrochloride extended-release tablet (GXR) is approved for child and adolescent patients with attention-deficit/hyperactivity disorder (ADHD). The aims of this study were to develop a population pharmacokinetic model of guanfacine after administration of GXR and to evaluate factors influencing the pharmaco...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2019.07.001

    authors: Tsuda Y,Matsuo Y,Matsumoto S,Wajima T

    更新日期:2019-12-01 00:00:00

  • A physiologically based pharmacokinetic model characterizing mechanism-based inhibition of CYP1A2 for predicting theophylline/antofloxacin interaction in both rats and humans.

    abstract::Clinical studies have revealed that some fluoroquinolones may cause severe adverse effects when co-administered with substrates of CYP1A2. Our previous study showed antofloxacin (ATFX) was responsible for mechanism-based inhibition (MBI) of the metabolism of phenacetin in rats. In the clinical setting, ATFX is likely ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-10-rg-126

    authors: Pan X,Wang P,Hu N,Liu L,Liu X,Xie L,Wang G

    更新日期:2011-01-01 00:00:00

  • Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).

    abstract::Thirty-nine genetic variations, including thirty novel ones, were found in the human SLC29A1 gene, which encodes equilibrative nucleoside transporter 1, from 256 Japanese cancer patients administered gemcitabine. The found novel variations included -8,166G>A, -81,10A>G, -7,947G>A, -7,789T>C, -5,595G>A, -3,803_-3,783de...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.21.248

    authors: Kim SR,Saito Y,Maekawa K,Sugiyama E,Kaniwa N,Ueno H,Okusaka T,Morizane C,Yamamoto N,Ikeda M,Yoshida T,Minami H,Furuse J,Ishii H,Saijo N,Kamatani N,Ozawa S,Sawada J

    更新日期:2006-06-01 00:00:00

  • Novel multiple assessment of hepatocellular drug disposition in a single packaged procedure.

    abstract:UNLABELLED:Better prediction of drug disposition prior to the clinical trial is critical for the efficient development of new drugs. The purpose of this study is to develop a novel multiple assessment methodology of hepatocellular drug disposition from drug uptake to efflux including biliary and basolateral excretion, ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2015.12.001

    authors: Takahashi R,Ichikawa H,Kanda K

    更新日期:2016-04-01 00:00:00

  • Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity.

    abstract::The work described in this study aimed to express CYP2C8 wild-type and mutant proteins in bacterial expression system and to use the expressed proteins to investigate the structural and functional consequences of a reported allele CYP2C8(*)4 (carrying Ile264Met substitution) on protein activity. Ile264 was replaced by...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.23.165

    authors: Singh R,Ting JG,Pan Y,Teh LK,Ismail R,Ong CE

    更新日期:2008-01-01 00:00:00

  • Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2.

    abstract::Genetic polymorphisms in xenobiotic transporters have recently been clarified to be associated with change in drug distribution and disposition. To expand on recent identification of direct interaction and functional regulation of several transporters by a PDZ (PSD95, Dlg and ZO1) domain containing protein PDZK1, the ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.21.375

    authors: Sugiura T,Kato Y,Kubo Y,Tsuji A

    更新日期:2006-10-01 00:00:00

  • Bonitos with low content of malodorous trimethylamine as palliative care for self-reported Japanese trimethylaminuria subjects.

    abstract::Trimethylaminuria is caused by excessive malodorous trimethylamine excreted via urine and body secretion by decreased hepatic flavin-containing monooxygenase 3 (FMO3) metabolic capacity for transforming non-odorous trimethylamine N-oxide. This study investigates foodstuff first in healthy volunteers for palliative car...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.24.549

    authors: Shimizu M,Kozono M,Murayama N,Yamazaki H

    更新日期:2009-01-01 00:00:00

  • Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions.

    abstract::Cytochrome P450 (P450) constitutes a superfamily of enzymes which activate dioxygen and carry out monooxygenation reactions of large numbers of endogenous and xenobiotic compounds. Drug metabolism is a particularly important P450 function, and, therefore, elucidating the metabolic products and pathways of drugs is ess...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2133/dmpk.20.1

    authors: Yasui H,Hayashi S,Sakurai H

    更新日期:2005-02-01 00:00:00

  • Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients.

    abstract::Tacrolimus is a widely used immunosuppressant after organ transplantation. The narrow therapeutic window and individual variability in tacrolimus pharmacokinetics make management of this agent a great challenge. This study was undertaken to determine the association of clinical markers, cytochrome P450, family 3, subf...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.dmpk-13-rg-095

    authors: Chen D,Guo F,Shi J,Zhang C,Wang Z,Fan J,Peng Z

    更新日期:2014-01-01 00:00:00

  • The population genetics of pharmacogenomics VIP variants in the Sherpa population.

    abstract::Polymorphic distributions of pharmacogenes among some ethnicities are under-represented in current pharmacogenetic research. Particularly, there is a paucity of pharmacogenetic information in the Sherpa population in Tibet. We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to de...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2015.11.007

    authors: Wang L,Ren Y,Shi X,Yuan D,Liu K,Geng T,Li G,Kang L,Jin TB

    更新日期:2016-02-01 00:00:00

  • Metabolomics study on the therapeutic effect of traditional Chinese medicine Xue-Fu-Zhu-Yu decoction in coronary heart disease based on LC-Q-TOF/MS and GC-MS analysis.

    abstract::The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in com...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2019.07.004

    authors: Yi M,Li Q,Zhao Y,Nie S,Wu N,Wang D

    更新日期:2019-10-01 00:00:00

  • Interpretation of the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo.

    abstract::UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of a wide variety of xeno/endobiotics. Previous studies have reported that human UGT enzymes are phosphorylated and that treatment of cells with protein kinase C (PKC) inhibitors results in decreased UGT activities without affecting the UGT protein level...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.DMPK-10-RG-121

    authors: Abe Y,Fujiwara R,Oda S,Yokoi T,Nakajima M

    更新日期:2011-06-01 00:00:00

  • Polymorphism of MDR1 gene in healthy japanese subjects: a novel SNP with an amino acid substitution (Glu108Lys).

    abstract::We discovered a novel single nucleotide polymorphism (SNP) at position 325 (G325A) in exon 5 of the multidrug-resistance 1 (MDR1) gene in a study of 37 healthy Japanese subjects. Details are as follows. SNP, 020614Honda001; GENE NAME, human P-glycoprotein (MDR1); ACCESSION NUMBER, M29427; LENGTH, 25 bases; 5'-ATGAATCT...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.17.479

    authors: Honda T,Dan Y,Koyabu N,Ieiri I,Otsubo K,Higuchi S,Ohtani H,Sawada Y

    更新日期:2002-01-01 00:00:00

  • Genetic variations in the MCT1 (SLC16A1) gene in the Chinese population of Singapore.

    abstract::MCT1(SLC16A1) is the first member of the monocarboxylate transporter (MCT) and its family is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study identifies genetic variations in SLC16A1 in the ethnic Chinese group of the Singaporea...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.24.469

    authors: Lean CB,Lee EJ

    更新日期:2009-01-01 00:00:00

  • Analysis of hepatic disposition of native and galactosylated polyethylenimine complexed with plasmid DNA in perfused rat liver.

    abstract::We studied the intrahepatic disposition characteristics of galactosylated polyethylenimine (Gal-PEI)/plasmid DNA (pDNA) complexes using rat liver perfusion experiment. After intraportal administration, transfection activity in liver of Gal-PEI complexes was approximately 26-fold higher than that of native PEI complexe...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.18.230

    authors: Fumoto S,Kawakami S,Ishizuka M,Nishikawa M,Yamashita F,Hashida M

    更新日期:2003-01-01 00:00:00

  • Safety evaluation and drug development based on biological fate of drugs -efforts made to overcome drug interaction in drug development-.

    abstract::1. Assay methods to detect drug interaction in toxicological samples were established by determining cytochrome P450 content and its activity in liver samples. The O-dealkylation reaction of 7-alkoxycoumarin was indicated to reflect changes in the molecular forms of P450s, and the enzyme induction or inhibition in the...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.17.379

    authors: Matsubara T

    更新日期:2002-01-01 00:00:00

  • Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.

    abstract::In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2018.08.006

    authors: Hikino K,Fukunaga K,Mushiroda T

    更新日期:2018-12-01 00:00:00

  • Effect of protein binding of pilsicainide on the pharmacokinetics.

    abstract::To evaluate the effect of protein binding of pilsicainide on its clearance and the contribution of protein binding to optimized pilsicainide therapy, clinical laboratory and pharmacokinetic data were studied in 160 Japanese inpatients (Study 1) and 18 Japanese inpatients (Study 2). To determine the relation between pr...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.20.183

    authors: Fukumoto K,Tanemura M,Tsuchishita Y,Kusumoto M,Matsumoto K,Kamakura S,Ueno K

    更新日期:2005-06-01 00:00:00

  • Altered expression of basement membrane-related molecules in rat brain pericyte, endothelial, and astrocyte cell lines after transforming growth factor-beta1 treatment.

    abstract::The basement membrane at the blood-brain barrier (BBB) plays important roles in maintaining the structure and function of capillary vessels. The BBB is constructed from endothelial cells, astrocytes and pericytes, but their interactions in the formation or maintenance of basement membrane have not been established. Tr...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.22.255

    authors: Kose N,Asashima T,Muta M,Iizasa H,Sai Y,Terasaki T,Nakashima E

    更新日期:2007-08-01 00:00:00

  • The regulation mechanism of AhR activated by benzo[a]pyrene for CYP expression are different between 2D and 3D culture of human lung cancer cells.

    abstract::Most of cytochrome P450 (CYP) expressions are regulated by nuclear receptors. The regulation pathways of transcription are activated by binding of the ligand to the receptor. Many combination of CYPs and nuclear receptors in transcriptional regulation have been reported. However, we have reported that the combination ...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2018.04.002

    authors: Terashima J,Jimma Y,Jimma K,Hakata S,Yachi M,Habano W,Ozawa S

    更新日期:2018-08-01 00:00:00

  • In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs.

    abstract::Since porphyrins are regarded as endogenous substrates for the ATP-binding cassette (ABC) transporter ABCG2, it is hypothesized that functional impairment owing to genetic polymorphisms or inhibition of ABCG2 by drugs may result in a disruption of cellular porphyrin homeostasis. In the present study, we expressed ABCG...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.22.428

    authors: Tamura A,Onishi Y,An R,Koshiba S,Wakabayashi K,Hoshijima K,Priebe W,Yoshida T,Kometani S,Matsubara T,Mikuriya K,Ishikawa T

    更新日期:2007-12-01 00:00:00

  • Nonlinear pharmacokinetics of aprindine in guinea pigs.

    abstract::After intravenous bolus administration of aprindine (AP) to conscious guinea pigs, the semilogarithmic plasma concentration versus time curve was linear at a dose of 2 mg/kg, but convex at doses of 5 and 10 mg/kg. AP concentrations immediately after administration (C(p0)) were almost identical, irrespective of the dos...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.17.292

    authors: Shimizu M,Ohota T,Kishida M,Ogata H

    更新日期:2002-01-01 00:00:00

  • A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates.

    abstract::The current EMA drug interaction guideline was published in 2012. This guideline gives important recommendations on the information required to elucidate the interaction potential of an investigational drug, both as effects of the investigational drug on the PK of other drugs and effects of other medicinal products on...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.1016/j.dmpk.2019.11.005

    authors: Cole S,Kerwash E,Andersson A

    更新日期:2020-02-01 00:00:00

  • Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors.

    abstract::In this study, a simple in vitro method for detecting human P450 (CYP) quasi-irreversible and irreversible inhibitors was evaluated. For the method, cDNA-expressed CYPs were applied to microtiter plate assays, CYP inhibitors were co-incubated with fluorometric substrates, and IC(50) were continuously measured (without...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.2133/dmpk.19.55

    authors: Naritomi Y,Teramura Y,Terashita S,Kagayama A

    更新日期:2004-02-01 00:00:00

  • 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients.

    abstract::The hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 is inhibited by some uremic toxins; however, direct inhibition can only partially explain the delayed systemic elimination of substrate drugs in renal failure patients. This study aimed to examine the long-lasting inhibition of OATP1B1 by...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2020.09.001

    authors: Masuo Y,Fujita KI,Mishiro K,Seba N,Kogi T,Okumura H,Matsumoto N,Kunishima M,Kato Y

    更新日期:2020-12-01 00:00:00

  • Appropriate risk criteria for OATP inhibition at the drug discovery stage based on the clinical relevancy between OATP inhibitors and drug-induced adverse effect.

    abstract::DDI could be caused by the inhibition of OATP-mediated hepatic uptakes. The aim of this study is to set the risk criteria for the compounds that would cause DDI via OATP inhibition at the drug discovery stage. The IC50 values of OATP inhibitors for human OATP-mediated atorvastatin uptake were evaluated in the expressi...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章

    doi:10.1016/j.dmpk.2016.05.003

    authors: Nakakariya M,Goto A,Amano N

    更新日期:2016-10-01 00:00:00

  • Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

    abstract::It is now widely appreciated that drug metabolites, in addition to the parent drugs themselves, can mediate the serious adverse effects exhibited by some new therapeutic agents, and as a result, there has been heightened interest in the field of drug metabolism from researchers in academia, the pharmaceutical industry...

    journal_title:Drug metabolism and pharmacokinetics

    pub_type: 杂志文章,评审

    doi:10.2133/dmpk.dmpk-10-rv-089

    authors: Baillie TA,Rettie AE

    更新日期:2011-01-01 00:00:00